Compare Eli Lilly And Co (LLY) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NVR Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,255.93 (market cap $1.08T), while NVR Inc. Common Stock trades at $6,029.24 (market cap $15.28B). The key difference: Eli Lilly And Co is far larger — about 70.7× NVR Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.57% dividend while NVR Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and NVR Inc. Common Stock for 0 Days on average.
| LLY | NVR | |
|---|---|---|
Market Cap | $1.08T | $15.28B |
Volume | 2,520,401 | 53,948 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $8.10K |
52-Week Low | $799.57 | $5.56K |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $15.18B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid a bullish technical outlook with strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights advancements in weight-loss and diabetes drugs, reinforcing growth prospects.
LLY's outlook remains positive, supported by a dominant position in obesity treatments and a promising pipeline. Risks include competitive pressures and high valuation multiples. Analyst consensus is strongly bullish with a $1,350 price target, though investors should monitor execution and regulatory developments.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
